Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 8, 2022, Rob Schott, M.D., M.P.H., F.A.C.C., Senior Vice President,
Head of Development of Sangamo Therapeutics, Inc. (the "Company"), notified the
Company of his resignation from this position and from his employment with the
Company, with such resignation to be effective on August 19, 2022, in order to
pursue a new opportunity. Dr. Schott's resignation is not due to any
disagreement with the Company on any matter relating to the Company's
operations, financial statements, internal controls, auditors, policies or
practices. Effective August 19, 2022, Nathalie Dubois-Stringfellow, Ph.D.,
currently serving as Senior Vice President, Product Development and Management,
will assume the role of Senior Vice President, Head of Development of the
Company.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses